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Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear J-B ligand levels, triglycerides, and coronary calcification in postmenopausal women Indu G. Poornima, MD, Rachel H. Mackey, PhD, MPH, Alhaji M. Buhari, MA, MSIE, Jane A. Cauley, DrPH, Karen A. Matthews, PhD, and Lewis H. Kuller, MD, DrPH The inverse association of total receptor activator of nuclear kappa-B (RANKL) with coronary artery calcium and triglycerides is a new finding and may have important implications, given increasing use of drugs that modify total RANKL and its receptor, RANK.
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Structured hypocaloric diet is more effective than behavioral therapy in reducing metabolic syndrome in Mexican postmenopausal women: a randomized controlled trial Otilia Perichart-Perera, PhD, RDN, Margie Balas-Nakash, MSc, Cinthya Muñoz-Manrique, MSc, Jennifer Legorreta-Legorreta, BS, Ameyalli Rodríguez-Cano, MCN, Jennifer Mier-Cabrera, PhD, and Jesús Rafael Aguilera-Pérez, MD A structured hypocaloric diet within a comprehensive nutrition intervention was more effective in reducing metabolic syndrome than a behavioral therapy approach. Both strategies were effective in reducing energy intake, body weight, and waist circumference after six months.
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Age at natural menopause in refugee and domicile women who lived in Tuzla Canton in Bosnia and Herzegovina during and after the war Devleta Bali(, MD, PhD, Mirzeta Rizvanovi(, MD, MSc, Mojca )izek-Sajko, PhD, and Adem Bali(, MD, PhD The age at onset of menopause in refugee women is lower than in domicile women, indicating that the factor of war, independently of other factors, could influence the age when menopause occurs. 
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Hormone therapy in oophorectomized BRCA1/2 mutation carriers Claudia Marchetti, MD, Roberta Iadarola, MD, Innocenza Palaia, MD, Violante di Donato, MD, Giorgia Perniola, MD, Ludovico Muzii, MD, and Perluigi Bendetti Panici, MD Prophylactic oophorectomy is recommended in BRCA1/2 mutation carriers; after careful selection, these patients may benefit from hormone therapy in order to reduce deterioration of quality of life related to estrogen deficiency.
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What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead? James A. Simon, MD, CCD, NCMP, IF, FACOG The author contemplates whether the WHI's outcomes would have been different had transdermal estradiol and oral progesterone replaced conjugated equine estrogens and medroxyprogesterone acetate. Statistical methods were used to ascertain population-attributable risk of VTE for transdermal estradiol versus oral hormone therapy, and imputes those risks into the WHI's primary outcomes.
Letter to the Editor 784
